Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-06-07
2000-03-14
Feisee, Lila
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241301, 4241411, 4241431, 4241441, 4241451, 424 852, 4241521, 4241551, 4241561, 4241581, 4241781, 530 8, 5303873, 5303877, 5303887, 5303896, 5303897, 5303917, A61K 39395
Patent
active
060369558
ABSTRACT:
Disclosed are various compositions and methods for use in achieving specific blood coagulation. This is exemplified by the specific in vivo coagulation of tumor vasculature, causing tumor regression, through the site-specific delivery of a coagulant using a bispecific antibody.
REFERENCES:
patent: 4456550 (1984-06-01), Dvorak et al.
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4536387 (1985-08-01), Sakamoto et al.
patent: 4785077 (1988-11-01), Kornbluth et al.
patent: 4975369 (1990-12-01), Beavers et al.
patent: 5017556 (1991-05-01), O'Brien et al.
patent: 5021236 (1991-06-01), Gries et al.
patent: 5081034 (1992-01-01), Bevilacqua et al.
patent: 5110730 (1992-05-01), Edgington et al.
patent: 5183756 (1993-02-01), Schlom
patent: 5202253 (1993-04-01), Esmon et al.
patent: 5223427 (1993-06-01), Edgington et al.
patent: 5242813 (1993-09-01), Pastan et al.
patent: 5298599 (1994-03-01), Rezaie et al.
patent: 5314695 (1994-05-01), Brown
patent: 5342757 (1994-08-01), Garin-Chesa et al.
patent: 5346991 (1994-09-01), Roy et al.
patent: 5374617 (1994-12-01), Morrissey et al.
patent: 5399346 (1995-03-01), Anderson et al.
patent: 5403713 (1995-04-01), Bevilaqua et al.
patent: 5437864 (1995-08-01), Edgington et al.
patent: 5504064 (1996-04-01), Morrissey et al.
patent: 5504067 (1996-04-01), Morrissey et al.
patent: 5589173 (1996-12-01), O'Brien et al.
patent: 5589363 (1996-12-01), Roy et al.
patent: 5632991 (1997-05-01), Gimbrone, Jr.
patent: 5726147 (1998-03-01), Ruf et al.
patent: 5739101 (1998-04-01), Roy et al.
Osborn et al., "Leukocyte Adhesion to Endothelium in Inflammation," Cell, 62:3-6, 1990.
June et al., "Role of the CD28 Receptor in T-Cell Activation," Immunology Today, 11(6):211-216, 1990.
Denekamp, "Vascular Attack as a Therapeutic Strategy for Cancer," Cancer and Metastasis Reviews, 9:267-282, 1990.
Scott et al., "Anti-CD3 Antibody Induces Rapid Expression of Cytokine Genes In Vivo," The Journal of Immunology, 145(7):2183-2188, 1990.
O'Connell and Edidin, "A Mouse Lymphoid Endothelial Cell Line Immortalized by Simian Virus 40 Binds Lymphocytes and Retains Functional Characteristics of Normal Endothelial Cells," The Journal of Immunology, 144(2):521-525, 1990.
Ledbetter et al., "CD 28 Ligation in T-Cell Activation: Evidence for Two Signal Transduction," Abstract only, Blood, 75(7):1531-1539, 1990.
Watanabe et al., "Exogenous Expression of Mouse Interferon .gamma. cDNA in Mouse Neuroblastoma C1300 Cells Results in Reduced Tumorigenicity by Augmented Anti-Tumor Immunity," Proceedings of the National Academy of Scientists, 86:9456-9460, 1989.
Schutt et al., "Human Monocyte Activation Induced by an Anti-CD14 Monoclonal Antibody," Immunology Letters, 19:321-328, 1988.
Thorpe et al., "Improved Antitumor Effects of Immunotoxins Prepared with Deglycosylated Ricin A-Chain and Hindered Disulfide Linkages," Cancer Research, 48:6396-6403, 1988.
Glennie et al., "Preparation and Performance of Bispecific (F(ab'.gamma.).sub.2 Antibody Containing Thioether-Linked Fab'.gamma. Fragments," The Journal of Immunology, 139(7):2367-2375, 1987.
Bevilacqua et al., "Identification of an Inducible Endothelial-Leukocyte Adhesion Molecule," Proceedings of the National Academy of Scientists, 84:9238-9242, 1987.
Cotran et al., "Induction and Detection of a Human Endothelial Activation Antigen In Vivo," Abstract only, The Journal of Experimental Medicine, 164(2):661-666, 1986.
Groenewegen et al., "Lymphokine Dependence of In Vivo Expression of MHC Class II Antigens by Endothelium," Nature, 316:361-263, 1985.
Moretta et al., Abstract only, The Journal of Experimental Medicine, 162(3):823-838, 1985.
Vaickus and Foon, "Overview of Monoclonal Antibodies in the Diagnosis and Therapy of Cancer," Cancer Investigation, 93(2):295-209, 1991.
Hagemeier et al., "A Monoclonal Antibody Reacting with Endothelial Cells of Budding Vessels in Tumors and Inflammatory Tissues, and Non-Reactive with Normal Adult Tissues," International Journal of Cancer, 38:481-488, 1986.
Duijvestijn et al., "Lymphoid Tissue-and Inflammation-Specific Endothelial Cell Differentiation defined by Monoclonal Antibodies," The Journal of Immunology, 138(3)713-719, 1987.
Murray et al., "Vascular Markers for Murine Tumours," Radiotherapy and Oncology, 16:221-234, 1989.
Schlingemann et al., "Monoclonal Antibody PAL-E Specific for Endothelium," Laboratory Investigation, 52(1):71-76, 1985.
Bruland et al., "New Monoclonal Antibodies Specific for Human Sarcomas," International Journal of Cancer, 38:27-31, 1986.
Reisfeld et al., "Human Tumor-Associated Antigens Defined by Monoclonal Antibodies," CRC Critical Reviews in Immunology, 5(1):27-53, 1984.
Schlom et al., "Monoclonal Antibodies Reactive with Breast Tumor-Associated Antigens," Advances in Cancer Research, 43:143-173, 1985.
Kaplan, "The Diagnostic and Therapeutic Use of Monoclonal Antibodies in Colorectal Cancer," Hematology/Oncology Clinics of North American, 3(1):125-134, 1989.
Smith and Teng, "Clinical Applications of Monoclonal Antibodies in Gynecologic Oncology," Cancer, 60:2068-2074, 1987.
Stavrou, "Monoclonal Antibodies in Neuro-Oncology," Neurosurgery Review, 13:7-18, 1990.
Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the Her2 Protooncogene to the Clinic," Journal of Clinical Immunology, 11(3):117-127, 1991.
Szymendera, "Clinical Usefulness of Three Monoclonal Antibody-Defined Tumor Markers: CA 19-9, CA 50, and CA 125," Tumour Biology, 7:333-342, 1986.
Catane and Longo, "Monoclonal Antibodies for Cancer Therapy," Israel Journal of Medical Sciences, 24:471-476, 1988.
Greiner et al., "Applications of Monoclonal Antibodies and Recombinant Cytokines for the Treatment of Human Colorectal and Other Carcinomas," Journal of Surgical Oncology Supplement, 2:9-13, 1991.
Thor and Edgerton, "Monoclonal Antibodies Reactive with Human Breast or Ovarian Carcinoma: In Vivo Applications," Seminars in Nuclear Medicine, 19(4):295-308, 1989.
Thorpe et al., "Selective Killing of Proliferating Vascular Endothelial Cells by an Anti-Fibronectin Receptor Immunotoxin," 16th LH Gray Conference, Sep. 17-21, 1990.
Ghose et al., "Preparation of Antibody-Linked Cytotoxic Agents," Methods in Enzymology, 93:280-333, 1983.
Thorpe et al., "Targeting to proliferating vascular endothelium," Int. Symp. on Angio., Mar. 13-15, 1991.
Knowles and Thorpe, "Purification of Immunotoxins Containing Ricin A-Chain and Abrin A-Chain Using Blue Sepharose CL-6B," Analytical Biochemistry, 160:440-443, 1987.
Wang et al., "Photoreactive In-Cyclodextrin Inclusion Complex: a New Heterobifunctional Reagent for Antibody Labeling," Nuclear Medicine and Biology, 19(8):897-902, 1992.
PCT Search Report mailed Jun. 25, 1993.
Alvarez et al., "Localization of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor in Human Glial Neoplasms," Modern Pathology, 5(3):303-307, 1992.
Brown et al., "Expression of Vascular Permeability Factor (Vascular Endothelial Growth Factor) and Its Receptors in Adenocarcinomas of the Gastrointestinal Tract," Cancer Research, 53;4727-4735, 1993.
Kim et al., "Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo," Nature, 362:841-843, 1993.
Dvorak et al., "Distribution of Vascular Permeability Factor (Vascular Endothelial Growth Factor) in Tumors: Concentration in Tumor Blood Vessels," J. Exp. Med., 174:1275-1278, 1991.
Gerlach et al., "Enhanced Responsiveness of Endothelium in the Growing/Motile State to Tumor Necrosis Factor/Cachectin," J. Exp. Med., 170:913-931, 1989.
Gougos et al., "Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts," International Immunology, 4(1):83-92, 1991.
Gougos et al., "Identification of a Human Endothelial Cell Antigen with Monoclonal Antibody 44G4 Produced Against a Pre-B Leukemic Cell Line," The Journal of Immunology, 141:1925-1933, 1988.
Gougos et al., "Biochemical Characterization of the 44G4 Antigen from the Hoon Pre-B Leukemic Cell Line," The Journal of Immunology, 141:1934-1940, 1988.
Hagemeier et al., "A Monoclona
Edgington Thomas S.
Thorpe Philip E.
Bansal Geetha P.
Board of Regents , The University of Texas System
Feisee Lila
The Scripps Research Institute
LandOfFree
Kits and methods for the specific coagulation of vasculature does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kits and methods for the specific coagulation of vasculature, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kits and methods for the specific coagulation of vasculature will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-166448